Catalent Aktie
| 63,49USD | 0,01USD | 0,02% |
WKN DE: A112H2 / ISIN: US1488061029
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,60 |
| The Vanguard Group, Inc. | 11,12 |
| Vanguard Group, Inc. (Subfiler) | 10,70 |
| Janus Henderson Investors US LLC | 7,30 |
| T. Rowe Price Investment Management, Inc. | 6,18 |
| Artisan Partners Holdings LP | 4,26 |
| State Street Corp. | 4,11 |
| Veritas Asset Management LLP | 3,56 |
| Capital Research & Management Co. (World Investors) | 3,53 |
| Capital Research & Management Co. (World Investors) | 3,53 |
| Corvex Management LP | 3,12 |
| Vanguard Total Stock Market ETF | 2,99 |
| BlackRock Fund Advisors | 2,96 |
| Vanguard 500 Index Fund | 2,64 |
| Norges Bank (13F) | 2,53 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 13 900 | 17 300 | 19 000 | 17 800 | 16 900 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,22 | 0,23 | 0,25 | 0,24 | 0,26 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 293 | 2 918 | 2 916 | 2 692 | 2 597 |
| Summe Anlagevermögen | 5 484 | 6 194 | 7 591 | 8 085 | 7 156 |
| Summe Aktiva | 7 777 | 9 112 | 10 507 | 10 777 | 9 753 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 4 271 | 4 838 | 5 712 | 6 166 | 6 149 |
| Summe Eigenkapital | 3 505 | 4 274 | 4 795 | 4 611 | 3 604 |
| Summe Passiva | 7 777 | 9 112 | 10 507 | 10 777 | 9 753 |
Adresse
| 14 Schoolhouse Road, 08873 Somerset | |
| Telefon | +1 (732) 537-6200 |
| Internet | http://www.catalent.com |
Management
|
Aristippos Gennadios
Group President-Pharma & Consumer Health |
|
Charles Lickfold
Chief Information Officer & Senior Vice President |
|
Frédéric Cédrone
Vice President-Corporate Innovation |
|
Joseph A. Ferraro
Secretary, Chief Compliance Officer & Senior VP |
|
Julien Meissonnier
Chief Scientific Officer & Vice President |
|
Karen Murphy Santiago
Vice President |
|
Lim Chin Wei
Manager-Global Scientific Affairs |
|
Lisa Evoli
Chief Human Resources Officer & Senior VP |
|
Matti Masanovich
Chief Financial Officer & Senior Vice President |
|
Michael J. Grippo
SVP-Strategy & Corporate Development |
|
Michael J. Hatzfeld
Chief Accounting Officer & Vice President |
|
Paul Surdez
Vice President-Investor Relations |
|
Ricardo Pravda
Chief Transformation Officer |
|
Ricardo Zayas
Senior VP-North America Biologic Operations |
|
Ricky Hopson
Chief of Staff & Head-Bio Product Delivery |
|
Scott Gunther
Senior Vice President-Quality & Regulatory Affairs |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
